Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Galena Biopharma Inc    

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 -
EBIT 2016 -33,9 M
Net income 2016 -23,9 M
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -28,6 M
Net income 2017 -27,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 0
Capi. / Sales2017 0
Capitalization 30,7 M
More Financials
Company
Galena Biopharma, Inc. engages as a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs.It focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of... 
Sector
Pharmaceuticals
Calendar
03/29Earnings Release
More about the company
Surperformance© ratings of Galena Biopharma Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on GALENA BIOPHARMA INC
12/01 GALENA BIOPHARMA, INC. : Other Events (form 8-K)
12/01 GALENA BIOPHARMA INC : . to Webcast, Live, at VirtualInvestorConferences.com Dec..
11/30 Galena Biopharma to Present Two Posters at the San Antonio Breast Cancer Symp..
11/15 GALENA BIOPHARMA : Presents GALE-301/GALE-302 Phase 1b Data at the Society for I..
11/14 Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the Society for ..
11/14 GALENA BIOPHARMA INC : REVERSE SPLIT: 1 of 20
11/14 GALENA BIOPHARMA INC : REVERSE SPLIT: 1 of 20
11/10 GALENA BIOPHARMA : reports 3Q loss
11/09 GALENA BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
11/09 GALENA BIOPHARMA, INC. : Results of Operations and Financial Condition, Regulati..
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/09 Galena Biopharma's (GALE) CEO Mark Schwartz on Q3 2016 Results - Earnings Cal..
11/09 Galena Biopharma beats by $0.02
11/08 Notable earnings after Wednesday?s close
11/03 RXI PHARMACEUTICALS : Moving On Promising Scar Treatment
08/24 Best And Worst Performing Stocks Of 2016
Advertisement
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | US3632561086 | 4-Traders
Full-screen chart
Technical analysis trends GALENA BIOPHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,7 $
Spread / Average Target 701%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark W. Schwartz President, Chief Executive Officer & Director
Sanford J. Hillsberg Chairman
Gavin S. Choy Senior VP-Clinical Sciences & Operations
Stephen F. Ghiglieri Chief Financial Officer & Executive Vice President
Bijan Nejadnik Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GALENA BIOPHARMA INC-87.52%31
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
More Results